Please Note:

The Open Access Repository has moved to a new authentication system as of the 1st of November.

Account holders will now be able to login using their University of Tasmania credentials.
If you have trouble logging in please email us on so we can assist you.

Public users can still access the records in this repository as normal

Open Access Repository

Technology evaluation: MRA, Chugai


Downloads per month over past year

Ding, C and Jones, G (2003) Technology evaluation: MRA, Chugai. Current Opinion in Molecular Therapeutics, 5 (1). pp. 64-69. ISSN 1464-8431

MRA.PDF | Download (52kB)
Available under University of Tasmania Standard License.

| Preview


Chugai, the Japanese subsidiary of Roche, is developing a
humanized anti-interleukin (IL)-6 receptor monoclonal antibody MRA for the potential treatment of multiple myeloma, rheumatoid arthritis, Crohn's disease and other IL-6-related disorders. MRA is currently undergoing phase II clinical trials for these indications.

Item Type: Article
Journal or Publication Title: Current Opinion in Molecular Therapeutics
Page Range: pp. 64-69
ISSN: 1464-8431
Date Deposited: 28 Mar 2008 00:57
Last Modified: 18 Nov 2014 03:31
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page